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Abstract: This explorative cross-sectional study aims at exploring emotional distress, psychological
profiles, and the attitude towards receiving psychological support in eighty-seven patients with
chronic migraine (CM) undergoing OnabotulinumtoxinA prophylactic treatment (OBT-A, n = 40)
or withdrawal treatment (WT, n = 47). The outcomes were explored through a specific battery of
questionnaires. 25% of patients undergoing OBT-A and almost half of the patients undergoing WT
reported psychological distress of at least moderate-severe level, respectively. Coping strategies,
self-efficacy, and perceived social support were similar in the two groups. Patients undergoing
OBT-A presented lower psychological inflexibility than patients undergoing WT. Predictors of higher
psychological distress were low perceived social support by friends, low self-efficacy, and higher
avoidance strategies. In both groups, most of the patients evaluated receiving psychological support
to be useful (79%). The potential beneficial effects of OBT-A on the severity of symptoms and
psychological distress might further support its role in the multidisciplinary management of patients
with CM. Identifying patients with psychological vulnerabilities who may benefit from psychological
support is relevant in patients with CM.
Keywords: chronic migraine; coping strategies; headache-related disability; psychological factors;
psychological distress; OnabotulinumtoxinA prophylactic treatment
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Key Contribution: Psychological distress is associated with avoidance, low self-efficacy and poor
perceived friends support in patients with CM. Patients undergoing OBT-A reported significantly
reduced psychological distress and inflexibility. Psychological support is an unmet need in patients
with CM.
1. Introduction
Migraine is one of the major causes of disability worldwide in adults under-50s [1,2]. Chronic
migraine (CM) represents the most severe and disabled portion of the migraine spectrum when
compared with both non-migraine and episodic migraine (EM). It affects patients’ wellbeing and
quality of life, with a negative impact on relationships, functioning, and personal roles [3–9]. CM is
defined as at least 15 days of headache per month for three months or more. Only eight of these headache
days per month need to meet migraine diagnostic criteria [10]. Different risk factors, including overuse
of acute migraine medication (MOH), ineffective acute treatment, obesity, depression, and stressful
life events have been related to migraine chronification, which occurs in about 2.5–3% of patients
with EM [11–13]. The observation that about 26% of patients with CM might reverse into remission
within two years of chronification [11] supports the importance of early identifying risks factors
for chronification and adopting an integrated treatment to improve their management. A variety
of psychological diagnoses, such as depression, anxiety, obsessive-compulsive, substance abuse,
sleep problems, and sub-threshold psychological symptoms, have often resulted in an association
with CM, as in other conditions leading to chronic pain [14–17]. For instance, the association between
migraine and psychological distress is higher in CM than in EM, especially in patients with MOH.
In this case, a high prevalence of psychopathological comorbidities has been reported [17–21]. Typically,
depression and anxiety symptoms increase with headache frequency and are associated with higher
levels of migraine-related disability [16,17,22–25]. However, in the clinical practice often psychological
distress is not reported in the physician-patient encounter, due, for example, to fear of stigmatization
or the tendency to suppress emotions [26–29].
The first-line management of CM is based on pharmacological treatment, according to the
pathophysiology of the disturbance [11]. However, the bulk of literature is focused on improving the
pharmacological outcome of this highly disabling disturbance through a multidisciplinary pathway of
care [30–37]. Psychological assessment and treatment for migraine should be integrated within this
multidisciplinary approach early, to enhance adherence to pharmacological and non-pharmacological
treatments and improve pain management, as in other neurological conditions causing chronic
pain, as suggested by the Italian Consensus Conference on Pain in Neurorehabilitation [38,39].
Several psychological constructs have been studied as potential mediators of psychological distress,
perceived pain, migraine management and prognosis (e.g., locus of control, self-efficacy, social
support, psychological flexibility, and coping strategies). These factors might be taken into account
in order to understand variation in disability and quality of life in CM [11,16,34,35,40–48] within
the conceptualization of migraine according to a bio-psycho-social model, where biological and
psychosocial factors are strictly interconnected [47,49].
To the best of our knowledge, most studies on psychological factors focused on patients with CM
and MOH, often during withdrawal treatment (WT). Only a few studies have explored psychological
factors during specific prophylaxis treatment, such as that with OnabotulinumtoxinA prophylactic
treatment (OBT-A). OnabotulinumtoxinA is an effective and well-tolerated treatment of CM [50],
reducing the severity of symptoms in terms of headache and migraine days, cumulative hours of
headache on headache days, and frequency of moderate/severe headache days. Therefore, a reduction
of the burden of illness in adults with disabling chronic migraine has been reported [50]. OBT-A has
been associated with a reduction in symptoms of depression and anxiety in patients with CM [51,52].
Although other studies reported no significant OBT-A benefit on psychological disturbances [53,54],
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an antidepressant effect of OBT-A has been suggested in different conditions [55,56]. In a recent
study [57], a clinically meaningful reduction of depression and anxiety symptoms, as measured using
self-reported questionnaires, emerged, even in the case of OBT-A non-responders in terms of reduction
of headache days. The potential mechanism of antidepressant action of OBT-A remains unknown.
In the case of patients with CM, the relief from the symptoms burden might induce, in turn, a reduction
of psychiatric symptoms. However, an OBT-A antidepressant effect per se has been hypothesized [57].
Interestingly, lower depression symptoms emerged as predictors of OBT-A responders [58,59]
and only patients without negative emotional states reported improved sleep quality as a benefit of
OBT-A [53]. Certain psychological features and personality traits (i.e., dependent trait) have been
associated with OBT-A non-response in patients with CM [60]. In our previous study, we reported that
specific coping strategies interfere with analgesic consumption and they are associated with different
acute medication consumptions behaviors in patients with CM undergoing OBT-A [61].
To sum up, the literature supports the importance to explore emotional distress and psychological
profiles in patients undergoing OBT-A and in other CM management phases. A more personalized
treatment approach, combining both pharmacological and non-pharmacological treatment options,
is warranted, especially in Italy [30].
In line with this background, the study aims to (i) describe psychological distress, self-efficacy,
coping strategies, perceived social support, psychological flexibility, and attitude towards psychological
support in a cohort of patients with CM attending OBT-A or WT; (ii) to characterize and compare
psychological distress and characteristics of patients undergoing OBT-A with patients undergoing
WT; and, (iii) to evaluate the factors influencing psychological distress, also considering the CM
management phase.
2. Results
2.1. Socio-Demographic and Clinical Characteristics
According to the selection criteria, 111 patients were eligible for inclusion in the two centers.
Thirteen patients receiving OBT-A and 11 attending WT declined to participate or did not sign informed
consent. Patients undergoing WT were all diagnosed with MOH, while seven patients (17.5%) among
those undergoing OBT-A reported medication overuse based on the screening of the drugs consumption
diary in the three months before the administration of the questionnaires. Moreover, half of these
patients reported a history of at least one WT.
Table 1 reports socio-demographic and clinical characteristics of the 87 participants. The two
groups were homogeneous for age, gender, educational level, and civil status. Female mainly composed
the sample. Most patients reported a severe migraine-related disability. However, patients with
OBT-A reported a lower percentage of severe migraine disability (80%) and a higher percentage of
mild-moderate one (20%) than patients attending WT (93.5% and 6.5%, respectively). The pain intensity
was rated at almost seven in both groups. Patients declared to have headaches for more than half days
of the previous three months on average; headache frequency was significantly higher for patients
attending WT (p < 0.01).
Table 1. Socio-Demographic and Clinical Characteristics of Patients distinguished by Treatment Group.
All Patients OBT-A Withdrawal Treatment
Socio-Demographic and
Clinical Characteristics N (%) N (%) N (%)
t-Test
or Chi2
Participants 87 40 (46.0) 47 (54.0)
Age, mean (SD) 46.2 (12.8) 46.8 (13.9) 45.7 (11.9) −0.4
Gender, female 76 (87.4) 37 (92.5) 39 (83.0) 1.8
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Table 1. Cont.
All Patients OBT-A Withdrawal Treatment
Socio-Demographic and




Secondary School 23 (27.4) 11 (28.2) 12 (26.7)
High School 34 (40.5) 13 (33.3) 21 (46.7)
Degree or Post Degree 27 (32.1) 15 (38.5) 12 (26.7) 1.8
Civil Status ◦
Single 24 (28.6) 12 (30.8) 12 (26.7)
Married or Unmarried Partner 51 (60.7) 24 (61.5) 27 (60.0)
Separated/Divorced/Widowed 9 (10.7) 3 (7.7) 6 (13.3) 0.8
Current Working Condition §
Not employed 28 (32.9) 11 (28.2) 17 (37.0)
Employed 57 (67.1) 28 (71.8) 29 (63.0) 0.7
Headache-related Disability
(MIDAS)
Low to Moderate Disability
(score < 21) ◦◦ 11 (12.8) 8 (20.0) 3 (6.5)
Severe disability (score ≥ 21) 75 (87.2) 32 (80.0) 43 (93.5) 3.5
MIDAS-C Headache
Frequency, mean (SD) ◦◦ 54.0 (30.3) 38.0 (23.5) 67.9 (28.8) −5.2 **
MIDAS-D Pain Intensity, mean
(SD) §§ 6.7 (2.0) 6.3 (1.6) 7.0 (2.2) −1.6
Legend: OBT-A, OnabotulinumtoxinA Prophylactic Treatment; N, number; %, percentage; SD, standard deviation;
MIDAS, Migraine Disability Assessment; ** p < 0.01; ◦ 3 missing values; § 2 missing values; ◦◦ 1 missing value;
§§ 6 missing values.
2.2. Psychosocial Characteristics and Psychological Distress in CM Sample
Table 2 reports psychological distress and characteristics. For the whole sample, 38% of patients
reported a General Severity Index (GSI-T score) equal to or higher than 55. The majority of included
patients presented coping strategies mean values that were comparable to those of the general
population included in the validation study of the Coping Orientation to the Problems Experienced
(COPE) [62], with higher use of social support (validation study mean = 27.7; DS = 8.4; t = 3.54 p < 0.01)
and of avoidance strategies (validation study mean = 23.5; DS = 5.1; t = 2.55 p = 0.01). The mean
values of the perceived social support resulted in line with the score that was reported in the Italian
validation study of the Multidimensional Scale of Perceived Social Support (MSPSS) [63], with a slightly
higher value for social support by a specific person (validation study mean = 5.6; DS = 1.4; t = 4.01
p < 0.01). The mean score of Acceptance and Action Questionnaire II (AAQ-II) shows a higher level of
psychological inflexibility (validation study mean = 20.1; DS = 7.3; t = 2.6; p = 0.01) [64]. Equal mean
values of perceived self-efficacy resulted when compared with D’Amico study (CM patients with MOH
mean = 2.9, DS = 0.5, t = 1.55, p = 0.12) [45].
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Table 2. Psychological Distress and Psychological Traits of Patients with chronic migraine (CM)
distinguished by Treatment Group.
All Patients OBT-A Withdrawal Treatment
Psychological Outcomes N (%) N (%) N (%) Chi2
Psychological Distress (SCL-90-R) §
General Severity Index (GSI) 8.0 *
T ≤ 54 53 (62.4) 30 (75.0) 23 (51.1)
T 55–64 18 (21.2) 8 (20.0) 10 (22.2)
T ≥ 65 14 (16.5) 2 (5.0) 12 (26.7)
Positive Symptom Distress Index 7.4 *
T < 54 63 (74.1) 35 (87.5) 28 (62.2)
T 55–64 15 (17.7) 4 (10.0) 11 (24.4)
T ≥ 65 7 (8.2) 1 (2.5) 6 (13.3)
Positive Symptom Total 11.4 **
T < 54 36 (42.4) 22 (55.0) 14 (31.1)
T 55–64 29 (34.1) 15 (37.5) 14 (31.1)
T ≥ 65 20 (23.5) 3 (7.5) 17 (37.8)
Mean (SD) Mean (SD) Mean (SD) t-test
Perceived Self-Efficacy (GSE) ◦◦ 2.8 (0.5) 2.8 (0.5) 2.8 (0.5) 0.4
Coping Strategies (COPE)
Social Support (COPE-SS) ◦ 30.6 (6.7) 29.9 (6.8) 31.1 (6.6) −0.8
Avoidance (COPE-AS) § 25.3 (6.2) 24.1 (5.1) 26.5 (6.9) −1.8
Positive Attitude (COPE-PA) § 30.8 (6.2) 29.9 (6.2) 31.7 (6.1) −1.3
Problem-Oriented (COPE-PO) § 31.3 (5.7) 30.8 (5.7) 31.8 (5.7) −0.8
Turning to Religion (COPE-TR) ◦ 22.0 (4.8) 22.3 (5.0) 21.8 (4.6) 0.5
Psychological Inflexibility (AAQ-II) ◦◦ 23.3 (10.5) 19.2 (8.9) 26.8 (10.5) −3.6 **
Perceived Social Support (MSPSS) ◦◦
By Significant Others (MSPSS-O) 6.0 (1.3) 5.9 (1.3) 6.2 (1.3) −0.8
By Family (MSPSS-FA) 5.8 (1.6) 5.7 (1.7) 5.8 (1.5) −0.3
By F0riends (MSPSS-FR) 4.8 (1.8) 4.5 (2.0) 5.1 (1.6) −1.6
Legend: OBT-A, OnabotulinumtoxinA Prophylactic Treatment; N, number; %, percentage; SD, standard deviation;
SCL-90-R, the Symptom Check List-90-R; GSE, the General Self-Efficacy Scale; COPE, Coping Orientation to the
Problems Experienced; SS, Social Support; AS, Avoidance Strategies; PA, Positive Attitude; PO, Problem Oriented;
TR, Turning to religion; AAQ-II, the Acceptance and Action Questionnaire II; MSPSS, Multidimensional Scale of
Perceived Social Support; O, by Significant Other; FA, by Family; FR, by friends; * p < 0.05; ** p < 0.01; ◦◦ 1 missing
value; § 2 missing values; ◦ 3 missing values.
2.3. Comparison of Psychosocial Characteristics and Psychological Distress: OBT-A versus WT
As reported in Table 2, 25% of patients attending the OBT-A reported a psychological distress of
at least moderate-severe level. Only 5% of patients attending OBT-A resulted over the clinical cut-off
(GSI-T > 65) against the 27% of patients attending WT. Similarly, the OBT-A group reported lower
Positive Symptoms and Positive Symptoms Distress than the group undergoing WT.
No significant differences in coping strategies, perceived self–efficacy, and perceived social support
were reported between groups. Conversely, patients attending OBT-A reported a significant lower
psychological inflexibility than WT, for whom the level of psychological inflexibility/experiential
avoidance also resulted in being higher than the one reported in the validation study of the Acceptance
and Action Questionnaire II (AAQ-II) (t = 0.73 p = 0.46 and t = 4.24 p < 0.01) [64].
2.4. Psychosocial Factors Influencing Psychological Distress
Pearson correlation coefficients showed that the psychological distress, as measured by GSI-T
scores, was strongly associated with psychological inflexibility and avoidance coping strategy (r = 0.7,
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p < 0.01 and r = 0.6; p < 0.01 respectively), followed by weak links with migraine frequency, perceived
self-efficacy, and perceived friend support (r = 0.3; p < 0.05 for MIDAS-C, MSPSS-FR, and GSE).
A more in-depth subgroup analysis on GSI-T scores, distinct for patients with CM undergoing
OBT-A and WT, underlined a different intensity between distress and perceived self-efficacy (r = −0.5,
p < 0.01 and r = −0.2, ns, respectively).
Table 3 reports the regression model that was performed over GSI-T scores, jointly considering
the variables that were deemed significant in the bivariate analysis.
Table 3. Psychological Factors influencing Psychological Distress.
Psychological Distress (GSI—T Score)
R2 = 0.51
Explanatory Variables Coef. [95% Conf. Interval]
Perceived Social Support by Friends (MSPSS-FR) −1.4 −2.4 −0.4
Avoidance Coping Strategies (COPE-AS) 0.8 0.5 1.1
Perceived Self-Efficacy (GSE) −5.3 −9.0 −1.6
Withdrawal Treatment (ref. OBT-A) 6.6 3.1 10.1
(Constant) 51.0 36.6 65.5
Legend: GSI—T score, Global Severity Index using a T-score approach; OBT-A, OnabotulinumtoxinA Prophylactic
Treatment; GSE, the General Self-Efficacy Scale; COPE, Coping Orientation to the Problems Experienced; AS,
Avoidance Strategies; MSPSS, Multidimensional Scale of Perceived Social Support; FR, by friends.
The resulting model explained 51% of GSI-T scores variation. Although CM management
phase predicted psychological distress (i.e., attending the WT predicted higher psychological
distress, confirming the higher level of psychological distress in this group), perceived social
support by friends, self-efficacy, and coping avoidance strategies all remained relevant independent
psychological predictors.
2.5. Psychological Support Received, Awareness of Psychological Problems and Opinion on the Utility of
Psychological Strategies for CM Management
As described in Table 4, 28% of patients with CM declared to have suffered, or currently suffer,
of a psychological problem, and 36% to have received or have been receiving psychological support
for distress linked to migraine.
Table 4. Attitude towards Psychological Support in patients with CM, distinguished by
Treatment Group.
All Patients OBT-A Withdrawal Treatment
Items N (%) N (%) N (%) Chi2
Suffering or having suffering of a
psychological problem
(self-reported) ◦◦—Yes
24 (27.9) 11 (28.2) 13 (27.7) 0.0
Receiving or having received
psychological support ◦◦—Yes 31 (36.1) 13 (33.3) 18 (38.3) 0.2
Interest for receiving
psychological strategies §§—Yes 64 (79.0) 28 (71.8) 36 (85.7) 2.4
Legend: OBT-A, OnabotulinumtoxinA Prophylactic treatment; N, number; %, percentage; SD, standard deviation;
◦◦ 1 missing value; §§ 6 missing values.
Seventy-nine per cent of responders considered it useful to receive psychological strategies,
with interest for psychological strategies reaching 86% for the patients attending the WT, although no
significant difference emerged between the two groups.
Regardless of the level of psychological distress, patients showed interest in receiving psychological
support in dealing with migraine distress. Only four patients (two in each sub-sample) among those
Toxins 2020, 12, 577 7 of 17
who declared not to be interested in receiving psychological strategies reported equal or higher values
than the GSI-T 55 score.
3. Discussion
This study explored the emotional distress and psychological profiles of patients with CM
attending two different programs of CM management: a withdrawal program for patients with MOH
in a hospital setting and a prophylactic program with periodical injections of OnabotulinumtoxinA in
an outpatient setting.
Patients attending OBT-A presented lower frequency of migraine attacks. However, the severity of
the migraine-linked disability and the socio-demographic characteristics of the two groups resulted in
being comparable. A high level of psychological distress emerged, with around one-third of the whole
sample presenting at least moderate-severe psychological distress. Among those patients, around 17%
reported very severe psychological distress over the clinical cut-off, suggesting a referral for a more
in-depth assessment of psychopathology. Psychological distress resulted in being particularly high
for patients undergoing WT, half of whom reported at least moderate-severe emotional distress.
These results confirmed previous researches, which highlighted multiple psychological comorbidities
in patients with MOH [21]. Saper and Lake [65] suggested the presence of one sub-group of patients
with MOH with a psychological dependence component, needing specific multidisciplinary approach
before and after withdrawal [66]. More recently, higher depression scores resulted in being associated
with a negative outcome for withdrawal [14] and baseline self-reported depression resulted associated
with the relapse in MOH and need for another WT at one year [67].
Although the percentage of patients with psychological distress over the clinical cut-off was low,
one out of four patients attending OBT-A presented at least a moderate-severe level of psychological
distress. Therefore, identifying patients presenting psychological vulnerabilities is also essential during
the OBT-A. On the one hand, it allows identifying patients with a poor predictor of OBT-A response,
due to the presence of depression and psychological distress [53,58,59,61]. On the other hand, patients
give more value, as assessed by clinicians, to the quality of life among OBT-A outcomes [68].
The reduced level of psychological distress within the OBT-A group might be partially explained
by previous literature. Patients undergoing WT reported very high frequent migraine attacks when
compared with the OBT-A group. Indeed, psychological distress might be associated with migraine
frequency when comparing CM versus EM or other categories of attack frequencies [16,17,24,25].
The higher level of psychological distress for patients undergoing WT might be associated with
the diagnosis of MOH. However, few patients undergoing OBT-A reported medication overuse
likewise. Previous studies reported that a reduced level of distress could be a beneficial effect of
the OBT-A [51,52,57]. The fact that we explored this potential association on a cross-sectional level
without assessing changes in clinical outcomes and psychological distress during OBT-A treatment
does not allow for us to evaluate whether the prophylactic treatment might influence clinical outcomes.
The longitudinal monitoring of the psychological distress in patients undergoing OBT-A might allow
investigating OBT-A clinical effect in reducing depression, anxiety, and other psychological symptoms.
Interestingly, patients attending OBT-A presented lower psychological inflexibility, similarly to
the general population scores: a psychological dimension related to a worse level of mental health as
well as the development and maintenance of higher levels of psychopathology [64,69]. In the migraine
field, the association between higher headache-related acceptance and lower level of depression and
anxiety has been suggested by Seng [34]. Coherently, psychological inflexibility resulted in being
strongly associated with headache-related disability in a previous study, including patients with
migraine (mainly EC) [44]. Conversely, MOH patients undergoing WT reported a high tendency to
experiential avoidance, and they also reported higher psychological inflexibility than the population of
the AAQ-II validation study, suggesting acceptance and values-based action as relevant psychological
dimensions to be fostered through appropriate psychological strategies for patients with MOH. Recently,
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Acceptance and Commitment Therapy (ACT) showed promising results in reducing adverse impact in
chronic pain conditions, including patients with migraine [32,70–73].
As regards coping strategies, a higher use of avoidance strategies was confirmed in the whole
sample, and avoidance resulted in being the only coping strategy associated to psychological distress,
suggesting the relevance of modifying this dysfunctional way to cope with stress when helping patients,
as already discussed [46]. Looking to the other coping strategies, our sample showed results that were
comparable to those reported in the validation study of the COPE [62], even with a higher use of social
support strategies. D’Amico [45] suggested the possible involvement of supportive relationships in the
prevention of MOH relapse. Perceived social support has been recognized as having a considerable
positive influence on mental health. However, the effect might vary, depending on the source of the
support [74]. Our study supports these results and shows that, in patients with CM, higher perceived
support by friends is associated with lower psychological distress. A slightly higher value for perceived
social support by “a specific person” compared to the general population emerged. Qualitative studies
have reported that patients with CM consider a close relationship helpful in the management of CM,
even though relationships and perception of social support can be “strained”, with others potentially
being “overprotective or undermining” [4]. Moreover, as in other chronic conditions, migraine might
affect the wellbeing of supporting people and the interpersonal dynamic thus affecting the patient’s
wellbeing [3].
Despite the different level of headache frequency, self-efficacy resulted in being similar in both
groups. Perceived self-efficacy has been considered a key factor in migraine management, adaptation
to pain, prevention and management at the onset or in the course of headache attacks and resulted
in being associated with headache-related disability [45,47,48,61]. Interestingly, only for patients
undergoing OBT-A low level of perceived self-efficacy resulted in being associated with higher
psychological distress.
Finally, as regards our third aim, higher use of avoidance strategies and lower self-efficacy
and friends support resulted in being related to higher psychological distress, beyond the different
severity of CM in the two groups. Tailored psychological interventions dedicated to these patients
might contribute to reduce emotional distress and psychological comorbidities and foster a more
functional psychological management of stressors of life, including the prevention and management
of headache attacks; all aspects that might influence the migraine-linked disability [34,45,75] and
long-term prognosis of CM, by influencing the threshold for the generation of migraine attacks [11].
As regards some practical implications of our findings, our study reinforced the need to adopt a
“patient-centered care” focus based on an integrated and multidisciplinary clinical assessment [29].
Validated psychological scales should be used for preliminary screening of psychological complaints
in patients with CM either in the presence of medication overuse or during the prophylactic treatment
using OBT-A. With this perspective, periodical OBT-A injections should be associated with periodical
psychological assessment other than the other clinical outcomes (e.g., disability scales, headache diary).
The outpatient OBT-A setting is relevant for the integrated psychosocial assessment and interventions
within a multidisciplinary perspective [76] involving different units. The outpatient context offers
opportunities, such as socialization and engagement, in valued actions at work, at home or in the
community, which represents a precise starting point for psychological and behavioral support.
Of note, the perspective of patients regarding psychological needs and support has been scarcely
explored in the context of CM [4,42]. In our study, most of the patients evaluated the utility of
psychological strategies for CM management positively, independently by the group, and even with
low psychological distress. Further studies are warranted to explore the patient’s motivation and
opinions on psychological interventions for CM, using focus groups or interviews. The patients definite
answer on receiving psychological strategies is a positive starting point to make complementary
behavioral interventions available. In the literature, the recognition of the role of psychosocial aspects
in migraine is increasing, with a definite interest in psychological approaches to be integrated with
pharmacological and medical ones and a growing interest in, and utilization of, complementary and
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integrative strategies, such as mindfulness-based interventions [37,38,73]. However, a gap between
research on the relevance and effectiveness of behavioral treatment interventions and the clinical
practice remains [37,77,78].
Strengths and Limitations
Having characterized the specific psychological aspects of different sub-populations of CM
patients attending different CM management phases, both in terms of psychological distress and
psychological profiles, extends previous findings and provides insights into the psychosocial needs of
a less studied group of patients with CM undergoing OBT-A.
The utilization of a self- reported instrument, like the SCL-90r, represents a strength of the
study, because it overcomes the only focus on depression and anxiety symptoms. Other psychological
symptoms other than depression and anxiety can be present and contribute to the overall distress of the
patient [19]. Moreover, this multidimensional scale of psychological distress can be useful for the initial
screening (but not for the diagnosis) of potential candidates for additional psychological assessment.
The over-representation of patients with very severe CM does not allow generalizing findings to
other contexts of care, or patients with migraine or CM managed in primary care, or not seeking medical
treatment. Finally, the study could not be balanced for gender since the results are mainly based on
a female cohort. Having most female patients among the sample resulted in line with the female
over-representation in this disorder [79]. However, social role expectations and coping styles differ
between genders potentially affecting the experience of headache and pain [80]. The two treatment
groups differed in the severity of the disease (frequency of attacks). The link between frequency and
distress was not explored in the study, thus representing a major weakness.
Further studies are needed, allowing for a better characterization of this population. Seven patients
undergoing OBT-A reported medication overuse according to the guidelines, and three of them reduced
the consumption of drugs in the three subsequent months below the level that was considered for
MOH diagnosis. Future studies should compare psychological distress and profiles between CM
patients with and without overuse in a larger sample of patients treated with OBT-A.
The cross-sectional nature of the current study did not allow us to assess changes in psychological
distress and factors over time, as previously discussed [61], or to verify whether OBT-A is influencing
distress directly or due to CM relief. These aspects should be further explored in a longitudinal study
evaluating psychological distress and factors from the baseline over OBT-A follow-up periodical
injections. Moreover, we were not able to test whether patients reported low self-efficacy, psychological
flexibility, perceived social support because of the psychological distress, or vice versa [45]. As regards
this causality hypothesis, from a clinical practice point of view, these psychological variables might
intersect with the psychological distress and contribute to its sustaining, creating a vicious circle that
maintains the suffering over time. As previously discussed, a multidisciplinary approach taking into
consideration all of these relevant bio-psycho-social aspects is necessary in order to detect the specific
role of these factors during each phase of CM management and introduce tailored intervention in order
to enhance the effect of specific CM treatment.
4. Conclusions
The current study shows the presence of different levels of psychological distress and psychological
profiles in patients with CM undergoing OBT-A or WT. The perceived level of psychological distress
is relevant in patients with medication overuse attending a withdrawal program, but it could not be
excluded, even in patients receiving OBT-A with lower symptoms severity. To conclude, it is worth
noting that most patients included in the study were interested in receiving psychological strategies
for the management of migraine. Psychological assessment and interventions might enhance the
therapeutic intervention in patients with CM within a bio-psycho-social framework.
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5. Materials and Methods
5.1. Study Design and Setting
A cross-sectional observational cohort study was performed from February 2018 to April 2019.
The study is part of the project “EXploring PsychoLOgical needs of patients with chronic pain attending
neuroREhabilitation services” (EXPLORE) [61]. Ethical approval to conduct the study was provided
by the Ethics Committee of the Verona and Rovigo Province in Italy (approval date: 17 January 2018,
1630CESC, Prog. n. 14112; 27 February 2018 Prog. 1667CESC, Prog. n. 11576).
The study was conducted through the strict collaboration among the UOC Neurorehabilitation and
the Unit of Clinical Psychology (University hospital, AOUI Verona, Verona, Italy) and the Neurological
Unit and the Clinical Psychological Service of the Scientific Institute for Research Hospitalisation and
Health Care (IRCSS) Sacro Cuore (Don Calabria Hospital, Negrar di Valpolicella, Italy). Since 2017,
these clinical centers collaborate for the management of CM patients in an interdisciplinary context
(neurologists, rehabilitation physicians, psychologists, physical therapists) to implement a pathway of
care in order to address the multiple factors (i.e., therapeutic exercise, myofascial dysfunction) that
may contribute to decreased migraine severity [31,61].
The patient refers to the specialist in Neurology at the IRCSS to define the diagnosis and plan
the pharmacological treatment according to the CM symptoms severity and the patients’ needs [50].
The OBT-A or WT decision was based according to the diagnosis and the clinical expertise of the single
neurologist (F.M.). In the presence of MOH (10 or more days/month of triptan/opioid intake or 15 or
more days/month of simple analgesics or combination for more than three months), the patient was
admitted to the Neurologic Unit for a 10-day hospitalization WT program [81]. Drug detoxification
was performed as an in-patient program and consisted of advice, steroids, anxiolytic drugs, fluid
replacement, and antiemetics preventive treatment [82]. Patients who have failed at least two to three
other migraine prophylactics were referred at the Neurorehabilitation Unit (AOUI Verona, Verona,
Italy) as an outpatient for the OBT-A prophylaxis [50]. It consists of OBT-A injection managed by the
same physician, during periodical outpatient visits every 12 weeks, according to the international
protocol [31,61].
5.2. Participants and Procedures
In the outpatient center, the patients were approached after the follow-up periodical outpatient
visit for OBT-A, while in the IRCCS of Negrar di Valpolicella during the hospitalization for the WT
program. Patients were assessed for eligibility according to the following inclusion criteria: fulfilment
of ICHD-III beta criteria for CM [10], as diagnosed by a neurologist (i.e., ≥15 headache days per
month, ≥8 of which are migraine days); age between 18 and 80; and, the ability to understand the
purpose of the study as evaluated by researchers approaching the patients. Patients who were already
evaluated for eligibility in one center were not considered to be eligible for recruitment in the other
one. After signing the informed written consent, participants entered the study and filled a series of
self-reported questionnaires.
5.3. Measures
Gender, age, educational level, civil status and work condition were collected through an ad
hoc form.
The impact of migraine on daily functioning over the past three months was assessed using
the Migraine Disability Assessment (MIDAS) Questionnaire [83]. The MIDAS total score—the sum
of five items examining the disability in school/work, household work, and family/social/leisure
activities—were categorized in four categories: I (MIDAS score 0–5), II (6–10), III (11–20), and IV
(>20), with grade IV corresponding to high disability level and grade I, II, III being collapsed in a
mild-moderate level. Two additional questions (MIDAS-C and MIDAS-D) asked patients to evaluate
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the number of days with headache (frequency of headache in the last three months) and the painfulness
of headache attacks (from 0 to 10).
Table 5 summarizes the main psychological variables that were explored in the study and describes
the self-reported questionnaires used. The scales have been previously used in the context of migraine
or clinical populations [41,45,61,84,85].
Table 5. List of Psychological Questionnaires adopted in the study.





90 items rated on a 5-point Likert scale (from “not at all” to “extremely”).
3 global indexes have been calculated:
• the global severity index (GSI)—an overall measure of
psychological distress;
• the positive symptom total (PST)—number of items scored above
zero, reflects the symptoms’ breadth;
• the positive symptom distress index (PSDI)—the average level of
distress for the self-reported symptoms, indicating the perceived
intensity of symptoms.
Data have been reported using a T-score approach: GSI or PST or PSDI,
T scores below the cut off of 55 indicate a level of the specific index similar
to the mean of the general population; T scores between 55 and 64 indicate
a moderate-severe level of psychological distress (GSI), a moderate-high a
number of symptoms (PST) and a moderate-high intensity of symptoms
(PSDI) respectively; at T scores higher than or equal to 65, the level of GSI







60 items rated on a 4-point scale (from “usually do not do this at all” to
“usually do this a lot”). 5 essentially, independent coping strategies have
been calculated:
• social support (COPE-SS)—seeking social support to obtain advice,
information or sympathy from others and express emotions;
• avoidance strategies (COPE-AS)—the attempts to avoid dealing with
either the problem or the associated emotions, including denial;
behavioural and mental disengagement; helplessness attitude and
substance utilization to reduce distress;
• positive attitude (COPE-PA)—the attitude of acceptance;
containment; positive reinterpretation of events and restraint-coping;
• problem-solving orientation (COPE-PO)—the active involvement in
dealing with the source of stress through taking steps to eliminate
the problem, planning and suppression of competing activities;







10 items rated on a 4-point scale (from “not at all true” to “exactly true”).






7 items on a 7-point scale (from “never true” to “always true”).
Higher scores correspond to higher levels of psychological inflexibility,
which is conceived experiential avoidance.
“The phenomenon that occurs when a person is unwilling to remain in
contact with particular private experiences (e.g., bodily sensations,
emotions, thoughts, memories, images, behavioural predispositions) and
takes steps to alter the form or frequency of these experiences or the








12 items rated on a 7-point scale (from “full disagreement” to “full
agreement”). 3 mean perceived support scores have been calculated:
perceived social support by family (MSPSS-FA), by friends (MSPSS-FR),
by significant others (MSPSS-O).
Finally, patients were asked to answer the following dichotomous questions: “Do you suffer or
have suffered in the past of a psychological problem?”, “Have you received, or are you receiving
psychological support for distress connected to migraine?”, and “Do you think that it might be useful
to receive suggestions on how to psychologically deal with migraine management?” This last question
aimed at exploring attitudes toward psychological support.
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5.4. Statistical Analysis
Psychological scale scores with more than 10% of item non-response were not calculated, so that a
pairwise deletion approach conducted the analysis. When less than 10% of responses were missing,
the averages of the available item responses were performed as the imputation method.
Descriptive statistics are presented as percentages, means, and standard deviations. Psychological
characteristics of the sample have been compared with values reported in the validation study of the
scale in order to better understand the psychological needs of the CM sample in comparison with the
general population, by using Student t-test for independent samples. T-test or chi-square test were
applied for comparing the socio-demographic, clinical, and psychological variables between the two
CM groups.
Pearson’s correlation coefficient was calculated to explore the relationships between psychological
variables. Multiple linear regression analyses were applied in order to explore the relationships among
the Global Severity Index (GSI)-T score, as the main outcome variable, socio-demographic and the
other psychological characteristics, as the explanatory ones. Regarding the choice of the final model,
a parsimonious criterion was applied to take the dimension of the sample into account.
The multi-center structure of the sample was accounted for in the regression models introducing
the center as a stratification variable, in order to consider the differences between OBT-A and WT
group and explain potential undetected features.
All of the analyses were performed using STATA 15.1 (StataCorp. 2017, College Station, TX, USA).
Author Contributions: Conceptualization, N.S. And L.D.P.; Data curation, V.D., M.A.M., M.G.
(Marialuisa Gandolfi), G.D., S.P. And L.D.P.; Formal analysis, M.A.M.; Methodology, V.D., M.A.M., M.G.
(Marialuisa Gandolfi) and L.D.P.; Supervision, L.D.P.; Writing—original draft, V.D., M.A.M., M.G. (Marialuisa
Gandolfi), S.B. And L.D.P.; Writing—review & editing, G.D., F.M., S.P., M.G. (Matteo Giansante), e.g., C.P. And N.S.
All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: Authors are thankful to all patients who participated in the research and to clinical trainees
(S. Bianconi, A. Ghellere, I. Vecchietti) in their support in collecting data and data entry. The authors thank I.
Montagni, International Medical Writer, Researcher at the University of Bordeaux for the English revision of
the paper.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Steiner, T.J.; Stovner, L.J.; Vos, T.; Jensen, R.; Katsarava, Z. Migraine is first cause of disability in under 50s:
Will health politicians now take notice? J. Headache Pain 2018, 19, 17. [CrossRef] [PubMed]
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national
incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries,
1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet (Lond. Engl.) 2017,
390, 1211–1259. [CrossRef]
3. Buse, D.C.; Fanning, K.M.; Reed, M.L.; Murray, S.; Dumas, P.K.; Adams, A.M.; Lipton, R.B. Life With
Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and
Outcomes (CaMEO) Study. Headache 2019, 59, 1286–1299. [CrossRef] [PubMed]
4. Nichols, V.P.; Ellard, D.R.; Griffiths, F.E.; Kamal, A.; Underwood, M.; Taylor, S.J.C. CHESS team The lived
experience of chronic headache: A systematic review and synthesis of the qualitative literature. BMJ Open
2017, 7, e019929. [CrossRef] [PubMed]
5. Allena, M.; Steiner, T.J.; Sances, G.; Carugno, B.; Balsamo, F.; Nappi, G.; Andrée, C.; Tassorelli, C. Impact of
headache disorders in Italy and the public-health and policy implications: A population-based study within
the Eurolight Project. J. Headache Pain 2015, 16, 100. [CrossRef]
Toxins 2020, 12, 577 13 of 17
6. Lantéri-Minet, M.; Duru, G.; Mudge, M.; Cottrell, S. Quality of life impairment, disability and economic
burden associated with chronic daily headache, focusing on chronic migraine with or without medication
overuse: A systematic review. Cephalalgia 2011, 31, 837–850. [CrossRef]
7. Raggi, A.; Schiavolin, S.; Leonardi, M.; Giovannetti, A.M.; Bussone, G.; Curone, M.; Di Fiore, P.; Grazzi, L.;
Usai, S.; D’Amico, D. Chronic migraine with medication overuse: Association between disability and quality
of life measures, and impact of disease on patients’ lives. J. Neurol. Sci. 2015. [CrossRef]
8. Buse, D.C.; Manack, A.N.; Fanning, K.M.; Serrano, D.; Reed, M.L.; Turkel, C.C.; Lipton, R.B. Chronic migraine
prevalence, disability, and sociodemographic factors: Results from the American migraine prevalence and
prevention study. Headache 2012, 52, 1456–1470. [CrossRef]
9. Blumenfeld, A.M.; Varon, S.F.; Wilcox, T.K.; Buse, D.C.; Kawata, A.K.; Manack, A.; Goadsby, P.J.; Lipton, R.B.
Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International
Burden of Migraine Study (IBMS). Cephalalgia 2011, 31, 301–315. [CrossRef]
10. Headache Classification Committee of the International Headache Society (IHS). The International
Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013, 33, 629–808. [CrossRef]
11. May, A.; Schulte, L.H. Chronic migraine: Risk factors, mechanisms and treatment. Nat. Rev. Neurol. 2016,
12, 455–464. [CrossRef] [PubMed]
12. Lipton, R.B. Tracing transformation: Chronic migraine classification, progression, and epidemiology.
Neurology 2009, 72, S3–S7. [CrossRef] [PubMed]
13. Manack, A.N.; Buse, D.C.; Lipton, R.B. Chronic migraine: Epidemiology and disease burden. Curr. Pain
Headache Rep. 2011, 15, 70–78. [CrossRef]
14. Bottiroli, S.; Allena, M.; Sances, G.; De Icco, R.; Avenali, M.; Fadic, R.; Katsarava, Z.; Lainez, M.J.A.;
Goicochea, M.T.; Bendtsen, L.; et al. Psychological, clinical, and therapeutic predictors of the outcome of
detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the
COMOESTAS Project. Cephalalgia 2019, 39, 135–147. [CrossRef]
15. Baldacci, F.; Lucchesi, C.; Cafalli, M.; Poletti, M.; Ulivi, M.; Vedovello, M.; Giuntini, M.; Mazzucchi, S.;
Del Prete, E.; Vergallo, A.; et al. Migraine features in migraineurs with and without anxiety-depression
symptoms: A hospital-based study. Clin. Neurol. Neurosurg. 2015, 132, 74–78. [CrossRef] [PubMed]
16. Seng, E.K.; Buse, D.C.; Klepper, J.E.; J. Mayson, S.; Grinberg, A.S.; Grosberg, B.M.; Pavlovic, J.M.;
Robbins, M.S.; Vollbracht, S.E.; Lipton, R.B. Psychological Factors Associated With Chronic Migraine and
Severe Migraine-Related Disability: An Observational Study in a Tertiary Headache Center. Headache 2017.
[CrossRef] [PubMed]
17. Buse, D.C.; Manack, A.; Serrano, D.; Turkel, C.; Lipton, R.B. Sociodemographic and comorbidity profiles
of chronic migraine and episodic migraine sufferers. J. Neurol. Neurosurg. Psychiatry 2010, 81, 428–432.
[CrossRef]
18. Curone, M.; Tullo, V.; Mea, E.; Proietti-Cecchini, A.; Peccarisi, C.; Bussone, G. Psychopathological profile of
patients with chronic migraine and medication overuse: Study and findings in 50 cases. Neurol. Sci. 2011.
[CrossRef]
19. Curone, M.; Tullo, V.; Lovati, C.; Proietti-Cecchini, A.; D’Amico, D. Prevalence and profile of obsessive-
compulsive trait in patients with chronic migraine and medication overuse. Neurol. Sci. 2014, 35, 185–187.
[CrossRef]
20. Cupini, L.M.; De Murtas, M.; Costa, C.; Mancini, M.; Eusebi, P.; Sarchielli, P.; Calabresi, P. Obsessive-
compulsive disorder and migraine with medication-overuse headache. Headache 2009, 49, 1005–1013.
[CrossRef]
21. Sarchielli, P.; Corbelli, I.; Messina, P.; Cupini, L.M.; Bernardi, G.; Bono, G.; Di Piero, V.; Petolicchio, B.;
Livrea, P.; Prudenzano, M.P.; et al. Psychopathological comorbidities in medication-overuse headache:
A multicentre clinical study. Eur. J. Neurol. 2016, 23, 85–91. [CrossRef]
22. Saunders, K.; Merikangas, K.; Low, N.C.P.; Von Korff, M.; Kessler, R.C. Impact of comorbidity on
headache-related disability. Neurology 2008. [CrossRef] [PubMed]
23. Lantéri-Minet, M.; Radat, F.; Chautard, M.-H.; Lucas, C. Anxiety and depression associated with migraine:
Influence on migraine subjects’ disability and quality of life, and acute migraine management. Pain 2005,
118, 319–326. [CrossRef] [PubMed]
Toxins 2020, 12, 577 14 of 17
24. Chu, H.-T.; Liang, C.-S.; Lee, J.-T.; Yeh, T.-C.; Lee, M.-S.; Sung, Y.-F.; Yang, F.-C. Associations Between
Depression/Anxiety and Headache Frequency in Migraineurs: A Cross-Sectional Study. Headache 2018,
58, 407–415. [CrossRef] [PubMed]
25. Buse, D.C.; Silberstein, S.D.; Manack, A.N.; Papapetropoulos, S.; Lipton, R.B. Psychiatric comorbidities of
episodic and chronic migraine. J. Neurol. 2013, 260, 1960–1969. [CrossRef]
26. Korkmaz, S.; Kazgan, A.; Korucu, T.; Gönen, M.; Yilmaz, M.Z.; Atmaca, M. Psychiatric symptoms in migraine
patients and their attitudes towards psychological support on stigmatization. J. Clin. Neurosci. 2019,
62, 180–183. [CrossRef]
27. Bottiroli, S.; Galli, F.; Viana, M.; Sances, G.; Tassorelli, C. Traumatic Experiences, Stressful Events,
and Alexithymia in Chronic Migraine With Medication Overuse. Front. Psychol. 2018, 9. [CrossRef]
28. Passchier, J.; Goudswaard, P.; Orlebeke, J.F.; Verhage, F. Migraine and defense mechanisms: Psychophysiological
relationships in young females. Soc. Sci. Med. 1988, 26, 343–350. [CrossRef]
29. Buse, D.C.; Lipton, R.B. Facilitating communication with patients for improved migraine outcomes. Curr. Pain
Headache Rep. 2008, 12, 230–236. [CrossRef]
30. Agostoni, E.C.; Barbanti, P.; Calabresi, P.; Colombo, B.; Cortelli, P.; Frediani, F.; Geppetti, P.; Grazzi, L.;
Leone, M.; Martelletti, P.; et al. Current and emerging evidence-based treatment options in chronic migraine:
A narrative review. J. Headache Pain 2019, 20, 92. [CrossRef]
31. Gandolfi, M.; Geroin, C.; Valè, N.; Marchioretto, F.; Turrina, A.; Dimitrova, E.; Tamburin, S.; Serina, A.;
Castellazzi, P.; Meschieri, A.; et al. Does myofascial and trigger point treatment reduce pain and analgesic
intake in patients undergoing onabotulinumtoxinA injection due to chronic intractable migraine? Eur. J.
Phys. Rehabil. Med. 2018, 54, 1–12. [CrossRef] [PubMed]
32. Grazzi, L.; Sansone, E.; Raggi, A.; D’Amico, D.; De Giorgio, A.; Leonardi, M.; De Torres, L.; Salgado-García, F.;
Andrasik, F. Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in
patients with Chronic Migraine: An effectiveness trial with a one-year follow-up. J. Headache Pain 2017,
18, 15. [CrossRef] [PubMed]
33. Nicholson, R.A.; Buse, D.C.; Andrasik, F.; Lipton, R.B. Nonpharmacologic Treatments for Migraine and
Tension-Type Headache: How to Choose and When to Use. Curr. Treat. Options Neurol. 2011, 13, 28–40.
[CrossRef] [PubMed]
34. Seng, E.K.; Kuka, A.J.; Mayson, S.J.; Smitherman, T.A.; Buse, D.C. Acceptance, Psychiatric Symptoms,
and Migraine Disability: An Observational Study in a Headache Center. Headache 2018, 58, 859–872.
[CrossRef] [PubMed]
35. Sauro, K.M.; Becker, W.J. Multidisciplinary treatment for headache in the Canadian healthcare setting. Can. J.
Neurol. Sci. 2008, 35, 46–56. [CrossRef] [PubMed]
36. Patel, S.; Potter, R.; Matharu, M.; Carnes, D.; Taylor, S.J.C.; Nichols, V.; Pincus, T.; Underwood, M.; Sandhu, H.
CHESS team Development of an education and self-management intervention for chronic headache—CHESS
trial (Chronic Headache Education and Self-management Study). J. Headache Pain 2019, 20, 28. [CrossRef]
37. Perlini, C.; Donisi, V.; Del Piccolo, L. From research to clinical practice: A systematic review of the
implementation of psychological interventions for chronic headache in adults. BMC Health Serv. Res. 2020,
20, 459. [CrossRef]
38. Castelnuovo, G.; Giusti, E.M.; Manzoni, G.M.; Saviola, D.; Gatti, A.; Gabrielli, S.; Lacerenza, M.;
Pietrabissa, G.; Cattivelli, R.; Spatola, C.A.M.; et al. Psychological Treatments and Psychotherapies in
the Neurorehabilitation of Pain: Evidences and Recommendations from the Italian Consensus Conference
on Pain in Neurorehabilitation. Front. Psychol. 2016, 7, 115. [CrossRef]
39. Castelnuovo, G.; Giusti, E.M.; Manzoni, G.M.; Saviola, D.; Gatti, A.; Gabrielli, S.; Lacerenza, M.; Pietrabissa, G.;
Cattivelli, R.; Spatola, C.A.M.; et al. Psychological Considerations in the Assessment and Treatment of
Pain in Neurorehabilitation and Psychological Factors Predictive of Therapeutic Response: Evidence and
Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. Front. Psychol.
2016, 7, 468. [CrossRef]
40. Matsuzawa, Y.; Lee, Y.S.C.; Fraser, F.; Langenbahn, D.; Shallcross, A.; Powers, S.; Lipton, R.; Simon, N.;
Minen, M. Barriers to Behavioral Treatment Adherence for Headache: An Examination of Attitudes, Beliefs,
and Psychiatric Factors. Headache 2019, 59, 19–31. [CrossRef]
Toxins 2020, 12, 577 15 of 17
41. Russo, A.; Santangelo, G.; Tessitore, A.; Silvestro, M.; Trojsi, F.; De Mase, A.; Garramone, F.; Trojano, L.;
Tedeschi, G. Coping Strategies in Migraine without Aura: A Cross-Sectional Study. Behav. Neurol. 2019,
2019, 5808610. [CrossRef] [PubMed]
42. Scaratti, C.; Covelli, V.; Guastafierro, E.; Leonardi, M.; Grazzi, L.; Rizzoli, P.B.; D’Amico, D.; Raggi, A.
A Qualitative Study On Patients With Chronic Migraine With Medication Overuse Headache: Comparing
Frequent And Non-Frequent Relapsers. Headache 2018, 58, 1373–1388. [CrossRef] [PubMed]
43. Sirri, L.; Pierangeli, G.; Cevoli, S.; Cortelli, P.; Grandi, S.; Tossani, E. Illness perception in patients with
migraine: An exploratory study in a tertiary care headache centre. J. Psychosom. Res. 2018, 111, 52–57.
[CrossRef] [PubMed]
44. Foote, H.W.; Hamer, J.D.; Roland, M.M.; Landy, S.R.; Smitherman, T.A. Psychological flexibility in migraine:
A study of pain acceptance and values-based action. Cephalalgia 2015, 36, 317–324. [CrossRef] [PubMed]
45. D’Amico, D.; Grazzi, L.; Bussone, G.; Curone, M.; Di Fiore, P.; Usai, S.; Leonardi, M.; Giovannetti, A.M.;
Schiavolin, S.; Raggi, A. Are depressive symptomatology, self-efficacy, and perceived social support related
to disability and quality of life in patients with chronic migraine associated to medication overuse? Data from
a cross-sectional study. Headache 2015, 55, 636–645. [CrossRef]
46. Wieser, T.; Walliser, U.; Womastek, I.; Kress, H.G. Dysfunctional coping in headache: Avoidance and
endurance is not associated with chronic forms of headache. Eur. J. Pain 2012, 16, 268–277. [CrossRef]
47. Nicholson, R.A.; Houle, T.T.; Rhudy, J.L.; Norton, P.J. Psychological risk factors in headache. Headache 2007,
47, 413–426. [CrossRef]
48. French, D.J.; Holroyd, K.A.; Pinell, C.; Malinoski, P.T.; O’Donnell, F.; Hill, K.R. Perceived self-efficacy and
headache-related disability. Headache 2000, 40, 647–656. [CrossRef]
49. Andrasik, F.; Flor, H.; Turk, D.C. An expanded view of psychological aspects in head pain: The biopsychosocial
model. Neurol. Sci. 2005. [CrossRef]
50. Bendtsen, L.; Sacco, S.; Ashina, M.; Mitsikostas, D.; Ahmed, F.; Pozo-Rosich, P.; Martelletti, P. Guideline on
the use of onabotulinumtoxinA in chronic migraine: A consensus statement from the European Headache
Federation. J. Headache Pain 2018, 19, 91. [CrossRef]
51. Boudreau, G.; Grosberg, B.; McAllister, P.; Lipton, R.; Buse, D. Prophylactic onabotulinumtoxinA in patients
with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety
and effect on headache-related disability, depression, and anxiety. Int. J. Gen. Med. 2015, 18, 79–86. [CrossRef]
[PubMed]
52. Zhang, H.; Zhang, H.; Wei, Y.; Lian, Y.; Chen, Y.; Zheng, Y. Treatment of chronic daily headache with
comorbid anxiety and depression using botulinum toxin A: A prospective pilot study. Int. J. Neurosci. 2017,
127, 285–290. [CrossRef] [PubMed]
53. Aydinlar, E.I.; Dikmen, P.Y.; Kosak, S.; Kocaman, A.S. OnabotulinumtoxinA effectiveness on chronic migraine,
negative emotional states and sleep quality: A single-center prospective cohort study. J. Headache Pain 2017,
18, 23. [CrossRef] [PubMed]
54. Guerzoni, S.; Pellesi, L.; Baraldi, C.; Pini, L.A. Increased efficacy of regularly repeated cycles with
OnabotulinumtoxinA in MOH patients beyond the first year of treatment. J. Headache Pain 2015, 17, 48.
[CrossRef] [PubMed]
55. Makunts, T.; Wollmer, M.A.; Abagyan, R. Postmarketing safety surveillance data reveals antidepressant
effects of botulinum toxin across various indications and injection sites. Sci. Rep. 2020, 10, 12851. [CrossRef]
[PubMed]
56. Magid, M.; Finzi, E.; Kruger, T.H.C.; Robertson, H.T.; Keeling, B.H.; Jung, S.; Reichenberg, J.S.; Rosenthal, N.E.;
Wollmer, M.A. Treating depression with botulinum toxin: A pooled analysis of randomized controlled trials.
Pharmacopsychiatry 2015, 48, 205–210. [CrossRef]
57. Blumenfeld, A.M.; Tepper, S.J.; Robbins, L.D.; Manack Adams, A.; Buse, D.C.; Orejudos, A.; D Silberstein, S.
Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression
and anxiety. J. Neurol. Neurosurg. Psychiatry 2019, 90, 353–360. [CrossRef]
58. Schiano di Cola, F.; Caratozzolo, S.; Liberini, P.; Rao, R.; Padovani, A. Response Predictors in Chronic
Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A
Treatment. Front. Neurol. 2019, 10, 678. [CrossRef]
Toxins 2020, 12, 577 16 of 17
59. Disco, C.; Bellamio, M.; Fuccaro, M.; Bruno, M.; Terrin, A.; Mainardi, F.; Zanchin, G.; Maggioni, F. O051.
Chronic migraine and onabotulinumtoxinA: A prospective study on patients treated at the Headache Centre
of the Padua University and analysis of possible predictors of responsivity. J. Headache Pain 2015, 16, A98.
[CrossRef]
60. Gonzalez-Martinez, A.; Rodríguez Vázquez, E.; Red Gallego, H.; García-Azorín, D.; Gallego de La Sacristana, M.;
Guerrero Peral, Á.L.; Gago-Veiga, A.B. Association Between Personality Traits and Onabotulinumtoxin A
Response in Patients With Chronic Migraine. Headache J. Head Face Pain 2020, 60, 153–161. [CrossRef]
61. Gandolfi, M.; Donisi, V.; Marchioretto, F.; Battista, S.; Smania, B.; Del Piccolo, L. A Prospective Observational
Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients
with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment. Toxins (Basel) 2019, 11, 504.
[CrossRef] [PubMed]
62. Sica, C.; Magni, C.; Ghisi, M.; Altoè, G.; Sighinolfi, C.; Chiri, L.R.; Franceschini, S. Coping Orientation to
Problems Experienced-Nuova Versione Italiana (COPE-NVI): Uno strumento per la misura degli stili di
coping. Psicoter. Cogn. Comport. 2008, 14, 27–53.
63. Prezza, M.; Principato, M.C. La rete sociale e il sostegno sociale. In Conoscere la Comunità; Prezza, M.,
Santinello, M., Eds.; Il Mulino: Bologna, Italy, 2002; pp. 193–233. ISBN 978-88-15-08782-9.
64. Monestès, J.-L.; Karekla, M.; Jacobs, N.; Michaelides, M.P.; Hooper, N.; Kleen, M.; Ruiz, F.J.; Miselli, G.;
Presti, G.; Luciano, C.; et al. Experiential Avoidance as a Common Psychological Process in European
Cultures. Eur. J. Psychol. Assess. 2018, 34, 247–257. [CrossRef]
65. Saper, J.R.; Lake, A.E. Medication overuse headache: Type I and type II. Cephalalgia 2006, 26, 1262. [CrossRef]
[PubMed]
66. Radat, F.; Lanteri-Minet, M. What is the role of dependence-related behavior in medication-overuse headache?
Headache 2010, 50, 1597–1611. [CrossRef]
67. Raggi, A.; Giovannetti, A.M.; Leonardi, M.; Sansone, E.; Schiavolin, S.; Curone, M.; Grazzi, L.; Usai, S.;
D’Amico, D. Predictors of 12-Months Relapse After Withdrawal Treatment in Hospitalized Patients With
Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache
2017, 57, 60–70. [CrossRef]
68. Tassorelli, C.; Aguggia, M.; De Tommaso, M.; Geppetti, P.; Grazzi, L.; Pini, L.A.; Sarchielli, P.; Tedeschi, G.;
Martelletti, P.; Cortelli, P. Onabotulinumtoxin A for the management of chronic migraine in current clinical
practice: Results of a survey of sixty-three Italian headache centers. J. Headache Pain 2017, 18, 66. [CrossRef]
69. Hayes, S.C.; Luoma, J.B.; Bond, F.W.; Masuda, A.; Lillis, J. Acceptance and commitment therapy: Model,
processes and outcomes. Behav. Res. Ther. 2006, 44, 1–25. [CrossRef]
70. Grazzi, L.; Bernstein, C.; Raggi, A.; Sansone, E.; Grignani, E.; Searl, M.; Rizzoli, P. ACT for migraine: Effect of
acceptance and commitment therapy (ACT) for high-frequency episodic migraine without aura: Preliminary
data of a phase-II, multicentric, randomized, open-label study. Neurol. Sci. 2019, 40, 191–192. [CrossRef]
71. Hughes, L.S.; Clark, J.; Colclough, J.A.; Dale, E.; McMillan, D. Acceptance and Commitment Therapy (ACT)
for Chronic Pain: A Systematic Review and Meta-Analyses. Clin. J. Pain 2017, 33, 552–568. [CrossRef]
72. Graham, C.D.; Gouick, J.; Krahé, C.; Gillanders, D. A systematic review of the use of Acceptance and
Commitment Therapy (ACT) in chronic disease and long-term conditions. Clin. Psychol. Rev. 2016, 46, 46–58.
[CrossRef] [PubMed]
73. Seng, E.K.; Singer, A.B.; Metts, C.; Grinberg, A.S.; Patel, Z.S.; Marzouk, M.; Rosenberg, L.; Day, M.; Minen, M.T.;
Lipton, R.B.; et al. Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related
Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial.
Headache 2019, 59, 1448–1467. [CrossRef] [PubMed]
74. Santini, Z.I.; Koyanagi, A.; Tyrovolas, S.; Mason, C.; Haro, J.M. The association between social relationships
and depression: A systematic review. J. Affect. Disord. 2015, 175, 53–65. [CrossRef]
75. Almarzooqi, S.; Chilcot, J.; McCracken, L.M. The role of psychological flexibility in migraine headache impact
and depression. J. Context. Behav. Sci. 2017, 6, 239–243. [CrossRef]
76. Tassorelli, C.; Tedeschi, G.; Sarchielli, P.; Pini, L.A.; Grazzi, L.; Geppetti, P.; De Tommaso, M.;
Aguggia, M.; Cortelli, P.; Martelletti, P. Optimizing the long-term management of chronic migraine with
onabotulinumtoxinA in real life. Expert Rev. Neurother. 2018, 18, 167–176. [CrossRef] [PubMed]
Toxins 2020, 12, 577 17 of 17
77. Minen, M.T.; Azarchi, S.; Sobolev, R.; Shallcross, A.; Halpern, A.; Berk, T.; Simon, N.M.; Powers, S.; Lipton, R.B.;
Seng, E. Factors Related to Migraine Patients’ Decisions to Initiate Behavioral Migraine Treatment Following
a Headache Specialist’s Recommendation: A Prospective Observational Study. Pain Med. 2018, 19, 2274–2282.
[CrossRef] [PubMed]
78. Penzien, D.B.; Irby, M.B.; Smitherman, T.A.; Rains, J.C.; Houle, T.T. Well-Established and Empirically
Supported Behavioral Treatments for Migraine. Curr. Pain Headache Rep. 2015, 19, 34. [CrossRef] [PubMed]
79. Vetvik, K.G.; MacGregor, E.A. Sex differences in the epidemiology, clinical features, and pathophysiology of
migraine. Lancet Neurol. 2017, 16, 76–87. [CrossRef]
80. Smitherman, T.A.; Ward, T.N. Psychosocial factors of relevance to sex and gender studies in headache.
Headache 2011, 51, 923–931. [CrossRef]
81. Evers, S.; Jensen, R. European Federation of Neurological Societies Treatment of medication overuse
headache—Guideline of the EFNS headache panel. Eur. J. Neurol. 2011, 18, 1115–1121. [CrossRef]
82. Diener, H.-C.; Holle, D.; Solbach, K.; Gaul, C. Medication-overuse headache: Risk factors, pathophysiology
and management. Nat. Rev. Neurol. 2016, 12, 575–583. [CrossRef]
83. Stewart, W.F.; Lipton, R.B.; Simon, D.; Von Korff, M.; Liberman, J. Reliability of an illness severity measure
for headache in a population sample of migraine sufferers. Cephalalgia 1998, 18, 44–51. [CrossRef]
84. Gajofatto, A.; Donisi, V.; Busch, I.M.; Gobbin, F.; Butturini, E.; Calabrese, M.; Carcereri de Prati, A.; Cesari, P.;
Del Piccolo, L.; Donadelli, M.; et al. Biopsychosocial model of resilience in young adults with multiple
sclerosis (BPS-ARMS): An observational study protocol exploring psychological reactions early after diagnosis.
BMJ Open 2019, 9, e030469. [CrossRef]
85. Sander, A.; Clark, A.; Arciniegas, D.; Leon-Novelo, L.; Ngan, E.; Sherer, M. A Randomized Controlled Trial
of Acceptance and Commitment Therapy in Persons With Traumatic Brain Injury. Arch. Phys. Med. Rehabil.
2019, 100, e166. [CrossRef]
86. Derogatis, L.R. The SCL-90-R Administration, Scoring, and Procedures Manual II for the R(evised) Version; Clinical
Psychometric Research: Towson, MD, USA, 1983.
87. Sarno, I.; Preti, E.; Prunas, A.; Madeddu, F. SCL-90-R Symptom Checklist-90-R Adattamento Italiano; Giunti O.S.:
Firenze, Italy, 2011; ISBN 978-88-09-74925-2.
88. Prunas, A.; Sarno, I.; Preti, E.; Madeddu, F.; Perugini, M. Psychometric properties of the Italian version of the
SCL-90-R: A study on a large community sample. Eur. Psychiatry 2012, 27, 591–597. [CrossRef]
89. Folkman, S.; Moskowitz, J.T. Coping: Pitfalls and promise. Annu. Rev. Psychol. 2004, 55, 745–774. [CrossRef]
90. Carver, C.S.; Scheier, M.F.; Weintraub, J.K. Assessing coping strategies: A theoretically based approach.
J. Pers. Soc. Psychol. 1989, 56, 267–283. [CrossRef]
91. Sibilia, L.; Schwarzer, R.; Jerusalem, M. Italian Adaptation of the General Self-Efficacy Scale: Self-Efficacy
Generalized. 1995. Available online: http://userpage.fu-berlin.de/~{}health/italian.htm (accessed on
24 July 2019).
92. Schwarzer, R.; Jerusalem, M. Generalized Self-Efficacy scale. In Measures in Health Psychology: A User—
s Portfolio. Causal and Control Beliefs; Weinman, J., Wright, S., Johnston, M., Eds.; NFER-NELSON: Windsor,
UK, 1995; pp. 35–37. Available online: http://userpage.fu-berlin.de/~{}health/selfscal.htm (accessed on
24 July 2019).
93. Scholz, U.; Doña, B.G.; Sud, S.; Schwarzer, R. Is general self-efficacy a universal construct? Psychometric
findings from 25 countries. Eur. J. Psychol. Assess. 2002, 18, 242–251. [CrossRef]
94. Bond, F.W.; Hayes, S.C.; Baer, R.A.; Carpenter, K.M.; Guenole, N.; Orcutt, H.K.; Waltz, T.; Zettle, R.D.
Preliminary psychometric properties of the Acceptance and Action Questionnaire-II: A revised measure of
psychological inflexibility and experiential avoidance. Behav. Ther. 2011, 42, 676–688. [CrossRef]
95. Hayes, S.C.; Strosahl, K.; Wilson, K.G.; Bissett, R.T.; Pistorello, J.; Toarmino, D.; Polusny, M.A.; Dykstra, T.A.;
Batten, S.V.; Bergan, J.; et al. Measuring experiential avoidance: A preliminary test of a working model.
Psychol. Rec. 2004, 54, 553–578. [CrossRef]
96. Zimet, G.D.; Dahlem, N.W.; Zimet, S.G.; Farley, G.K. The Multidimensional Scale of Perceived Social Support.
J. Pers. Assess. 1988, 52, 30–41. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
